EUVIMEDEUVIMED entdecken
Crossref

Cancer‐Associated Fibroblast Signature Can Predict Prognosis and Therapeutic Responses in Skin Cutaneous Melanoma

Yue Zheng, Weihuan Shao, Tongxin Ge, Shengfang Ge, Renbing Jia, Ludi Yang, Ai Zhuang iD

Pigment Cell & Melanoma Research · 2025-03 · 38 (2)

DOI: 10.1111/pcmr.70005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 26.02.2025. Verfasst von Yue Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Eye Health, Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai,…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin cutaneous melanoma (SKCM) is a lethal skin cancer with a poor prognosis and limited response to immunotherapy. Cancer‐associated fibroblasts (CAFs) are key contributors to tumor progression, therapy resistance, and immunosuppression. In this study, mRNA sequencing and clinical data from SKCM samples were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to evaluate the prognostic significance, therapeutic implications, and potential for enhancing immunotherapy through targeting CAFs in SKCM. A CAF‐related risk model comprising nine genes was developed, revealing that patients classified as low‐risk exhibited superior survival outcomes and increased sensitivity to immunotherapy. Spearman correlation analysis identified significant associations between the risk score and the sensitivity to 40 drugs, as well as resistance to 17 drugs. Additionally, CAFs were categorized into three distinct subgroups in SKCM, with antigen‐presenting CAFs (apCAFs) notably suppressing the infiltration of anti‐tumor immune cells and strongly correlating with poor prognosis. In summary, the CAF‐related risk model offers a robust prognostic tool for SKCM, capable of predicting both survival outcomes and therapeutic sensitivity. Moreover, the pivotal role of apCAFs within the immune microenvironment suggests that targeting these cells may enhance the efficacy of immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsCancer-Associated FibroblastsHumansPrognosisCutaneous Malignant MelanomaTumor MicroenvironmentGene Expression Regulation, NeoplasticImmunotherapyFemaleMale

Stichwörter der Autor:innen

cancer‐associated fibroblastsimmunotherapyprognosisskin cutaneous melanomatherapeutic responses

Autor:innen und Institutionen

  • State Key Laboratory of Eye Health, Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, People's Republic of China.

ORCID-Profile: Ai Zhuang

Zitieren

APA

Zheng, Y., Shao, W., Ge, T., Ge, S., Jia, R., Yang, L., & Zhuang, A. (2025). Cancer‐Associated Fibroblast Signature Can Predict Prognosis and Therapeutic Responses in Skin Cutaneous Melanoma. Pigment Cell & Melanoma Research, 38(2). https://doi.org/10.1111/pcmr.70005

Vancouver

Zheng Y, Shao W, Ge T, Ge S, Jia R, Yang L, et al. Cancer‐Associated Fibroblast Signature Can Predict Prognosis and Therapeutic Responses in Skin Cutaneous Melanoma. Pigment Cell & Melanoma Research. 2025;38(2). doi:10.1111/pcmr.70005

BibTeX
@article{Zheng2025,
  author = {Zheng, Yue and Shao, Weihuan and Ge, Tongxin and Ge, Shengfang and Jia, Renbing and Yang, Ludi and Zhuang, Ai},
  title = {Cancer‐Associated Fibroblast Signature Can Predict Prognosis and Therapeutic Responses in Skin Cutaneous Melanoma},
  journal = {Pigment Cell & Melanoma Research},
  year = {2025},
  volume = {38},
  number = {2},
  doi = {10.1111/pcmr.70005}
}
Kostenlos starten →